These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9192169)

  • 21. Normalization of lens protein kinase Cgamma in galactosemic dogs by a novel aldose reductase inhibitor.
    Takemoto DJ; Harris R; Brightman A; McGill J; Hua D; Davidson H; Fenwick B; Wagner LM
    Vet Ophthalmol; 2004; 7(3):163-7. PubMed ID: 15091323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
    Robison WG; Laver NM; Jacot JL; Glover JP
    Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2368-80. PubMed ID: 7591626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of aldose reductase inhibitor, statil, on hyperpermeability of iridial vessels in experimental galactosemic rats.
    Terubayashi H; Akagi Y
    Jpn J Ophthalmol; 1989; 33(3):343-7. PubMed ID: 2507812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs.
    Cusick M; Chew EY; Ferris F; Cox TA; Chan CC; Kador PF
    Arch Ophthalmol; 2003 Dec; 121(12):1745-51. PubMed ID: 14662595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose.
    Kador PF; Betts D; Wyman M; Blessing K; Randazzo J
    Am J Vet Res; 2006 Oct; 67(10):1783-7. PubMed ID: 17014334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation.
    Ohashi Y; Awata T; Sogo S; Ohira M; Matsuda M; Fukuda M; Manabe R
    J Ocul Pharmacol; 1989; 5(4):325-8. PubMed ID: 2516866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of treatment after measurable diabeticlike retinopathy in galactose-fed rats.
    Robison WG; Laver NM; Jacot JL; Chandler ML; York BM; Glover JP
    Invest Ophthalmol Vis Sci; 1997 May; 38(6):1066-73. PubMed ID: 9152226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of corneal epithelial barrier function with the slit-lamp fluorophotometer.
    Yokoi N; Kinoshita S
    Cornea; 1995 Sep; 14(5):485-9. PubMed ID: 8536461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF; Inoue J; Secchi EF; Lizak MJ; Rodriguez L; Mori K; Greentree W; Blessing K; Lackner PA; Sato S
    Exp Eye Res; 1998 Aug; 67(2):203-8. PubMed ID: 9733586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.
    Sato S; Mori K; Wyman M; Kador PF
    Exp Eye Res; 1998 Feb; 66(2):217-22. PubMed ID: 9533847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and evaluation of novel aldose reductase inhibitors: Effects on lens protein kinase Cgamma.
    Lewis S; Karrer J; Saleh S; Chan X; Tan Z; Hua D; McGill J; Pang YP; Fenwick B; Brightman A; Takemoto D
    Mol Vis; 2001 Jul; 7():164-71. PubMed ID: 11483892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
    Forster HG; ter Wee PM; Hohman TC; Epstein M
    Diabetologia; 1996 Aug; 39(8):907-14. PubMed ID: 8858212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A; Diecke FP; Mistry K; Cruz E
    Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The inhibitory effect of aldose reductase inhibitor for proliferation in the lens epithelial cells of rat sugar cataract].
    Morikubo S; Takamura Y; Kubo E; Tsuzuki S; Akagi Y
    Nippon Ganka Gakkai Zasshi; 2003 Oct; 107(10):565-70. PubMed ID: 14598706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat.
    Robison WG; Kador PF; Akagi Y; Kinoshita JH; Gonzalez R; Dvornik D
    Diabetes; 1986 Mar; 35(3):295-9. PubMed ID: 3081393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of beta-blocker eyedrops on corneal epithelial barrier function.
    Niiya A; Yokoi N; Matsumoto Y; Komuro A; Ishibashi T; Tomii S; He J; Kinoshita S
    Ophthalmologica; 2000; 214(5):332-6. PubMed ID: 10965246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ciliary body changes associate with aldose reductase in galactosemic rats (2)].
    Ikebe H; Terubayashi H; Okamoto S; Matsumoto Y; Tsutsumi M; Ibaraki N; Akagi Y
    Nippon Ganka Gakkai Zasshi; 1992 Jul; 96(7):860-4. PubMed ID: 1502985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of substance P, insulin-like growth factor-1 and vasoactive intestinal polypeptide on corneal re-epithelialization in galactosemic rats.
    McDermott AM; Kern TS; Reid TW; Russell P; Murphy CJ
    Curr Eye Res; 1998 Dec; 17(12):1143-9. PubMed ID: 9872536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.